title: Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2.
abstract: OBJECTIVE
  This analysis of the Lipid Treatment Assessment Project 2 population compared lipid goal attainment by diabetes and metabolic syndrome status.
  
  
  METHODS
  Dyslipidaemic patients aged ≥ 20 years on stable lipid lowering therapy had their lipid levels determined once during enrolment at investigation sites in nine countries between September 2006 and April 2007. Achievement of low-density lipoprotein (LDL) cholesterol success, triglycerides < 150 mg/dl (1.7 mmol/l), and high-density lipoprotein (HDL) cholesterol success (> 40 mg/dl [1.0 mmol/l] in men or > 50 mg/dl [1.3 mmol/l] in women) was compared using logistic regression.
  
  
  RESULTS
  A total of 9955 patients were evaluated. Patients with diabetes, compared with those without diabetes, had lower achievement of LDL cholesterol goals (according to National Cholesterol Education Program Adult Treatment Panel [NCEP ATP] III guidelines; 67% vs. 75%), triglycerides < 150 mg/dl (55% vs. 64%), and HDL cholesterol success (61% vs. 74%; p < 0.0001 for all comparisons). The significantly lower lipid goal attainment in patients with diabetes was consistent across participating world regions. Patients with metabolic syndrome, compared with those without metabolic syndrome, had lower achievement of NCEP ATP III LDL cholesterol goals (69% vs. 76%), triglycerides < 150 mg/dl (36% vs. 83%), and HDL cholesterol success (49% vs. 89%; p < 0.0001 for all comparisons). As the number of metabolic syndrome components increased, lipid success rates progressively decreased (p < 0.0001 for LDL cholesterol success, triglycerides < 150 mg/dl, and HDL cholesterol success).
  
  
  CONCLUSIONS
  This analysis indicates that despite their increased cardiovascular risk, patients with diabetes or metabolic syndrome remain undertreated.
authors.affiliation: Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. j.w.jukema@lumc.nl
authors.forename: J Wouter
authors.initials: JW
authors.lastname: Jukema
authors.forename: Cheng-Wen
authors.initials: CW
authors.lastname: Chiang
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrières
authors.forename: Raul D
authors.initials: RD
authors.lastname: Santos
authors.forename: Juan
authors.initials: J
authors.lastname: Verdejo
authors.forename: David D
authors.initials: DD
authors.lastname: Waters
authors.forename: Michael
authors.initials: M
authors.lastname: Messig
authors.forename: Lisa
authors.initials: L
authors.lastname: Tarasenko
mesh_terms: D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003920:Diabetes Mellitus / Q000097:blood / Q000503:physiopathology*; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D006801:Humans; D038622:Internationality; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000503:physiopathology*; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL